Cytomegalovirus Clinical Trials

53 recruitingLast updated: June 18, 2026

There are 53 actively recruiting cytomegalovirus clinical trials across 22 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, San Francisco, California, United States, Paris, France. Updated daily from ClinicalTrials.gov.


Cytomegalovirus Trials at a Glance

53 actively recruiting trials for cytomegalovirus are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Houston, San Francisco, and Paris. Lead sponsors running cytomegalovirus studies include Takeda, Assistance Publique - Hôpitaux de Paris, and Columbia University.

Browse cytomegalovirus trials by phase

Treatments under study

About Cytomegalovirus Clinical Trials

Looking for clinical trials for Cytomegalovirus? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cytomegalovirus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cytomegalovirus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 53 trials

Recruiting

Comparison Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With intestinalBOweL Diseases

Cytomegalovirus (CMV)Inflammatory Bowel Disease (IBD)
IRCCS Azienda Ospedaliero-Universitaria di Bologna200 enrolled1 locationNCT06793124
Recruiting
Phase 1

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Cytomegalovirus Prophylaxis
Merck Sharp & Dohme LLC40 enrolled17 locationsNCT07199465
Recruiting
Phase 3

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Cytomegalovirus InfectionsKidney Transplant InfectionPancreas Transplant
University of Wisconsin, Madison90 enrolled1 locationNCT06407232
Recruiting
Phase 1

R-MVST Cells for Treatment of Viral Infections

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsBK Virus Infection+1 more
Columbia University36 enrolled1 locationNCT05183490
Recruiting

Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection

Sensorineural Hearing LossViral InfectionCytomegalovirus Infections+2 more
Rigshospitalet, Denmark630 enrolled2 locationsNCT07635368
Recruiting

Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals

Cytomegalovirus InfectionsMaternal Primary Cytomegalovirus Infection
Assistance Publique - Hôpitaux de Paris491 enrolled3 locationsNCT06694428
Recruiting

A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina

Cytomegalovirus (CMV)
Takeda10 enrolled1 locationNCT06213974
Recruiting
Phase 2

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Cytomegalovirus InfectionsTransplant-Related Disorder
University of Pennsylvania80 enrolled1 locationNCT06066957
Recruiting
Not Applicable

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Hematopoietic Cell TransplantCytomegalovirus Cell Mediated Immunity
M.D. Anderson Cancer Center105 enrolled1 locationNCT06639854
Recruiting
Phase 4

Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationCytomegalovirus Infections+1 more
WeiShi120 enrolled12 locationsNCT07569653
Recruiting
Phase 1

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
National Institute of Allergy and Infectious Diseases (NIAID)12 enrolled10 locationsNCT06118515
Recruiting
Phase 3

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

Cytomegalovirus (CMV)
Takeda80 enrolled53 locationsNCT05319353
Recruiting
Early Phase 1

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Allogeneic Hematopoietic Stem Cell Transplantation RecipientAdenovirusCytomegalovirus+2 more
Sumithira Vasu20 enrolled2 locationsNCT03665675
Recruiting
Phase 2

Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)

Cytomegalovirus Viraemia
Murdoch Childrens Research Institute232 enrolled7 locationsNCT06574789
Recruiting

Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation

cytomegalovirus infectionHematopoietic Stem Cells Transplantation
MSD Italia S.r.l.230 enrolled5 locationsNCT06916195
Recruiting
Phase 3

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

Kidney Transplant; ComplicationsKidney DiseasesCytomegalovirus (CMV)
University of California, San Francisco360 enrolled5 locationsNCT06798909
Recruiting

Immunological and Virological Prognostic Markers of Human Cytomegalovirus (HCMV) Congenital Infection in Pregnant Women With Primary HCMV Infection.

Human Cytomegalovirus (HCMV)
Fondazione IRCCS Policlinico San Matteo di Pavia90 enrolled1 locationNCT07477925
Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

cytomegalovirus infection
ModernaTX, Inc.224 enrolled3 locationsNCT05683457
Recruiting

Breakthrough CMV Lung Transplant -Multicentre

Cytomegalovirus Infections
University of Alberta40 enrolled1 locationNCT04439916
Recruiting
Phase 3

A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Cytomegalovirus (CMV)
Takeda20 enrolled12 locationsNCT06439342